Biology of platelet-derived growth factor and its involvement in disease

被引:291
作者
Alvarez, Ricardo H.
Kantarjian, Hagop M.
Cortes, Jorge E.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA
关键词
D O I
10.4065/81.9.1241
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelet-derived growth factor (PDGF) is mainly believed to be an important mitogen for connective tissue, especially for fibroblasts that serve in wound healing. However, PDGF also has important roles during embryonal development, and its overexpression has been linked to different types of fibrotic disorders and malignancies. Platelet-derived growth factor is synthesized by many different cell types, and its expression is broad. Its synthesis is in response to external stimuli, such as exposure to low oxygen tension, thrombin, or stimulation by other cytokines and growth factors. In addition, PDGF may function in autocrine stimulation of tumor cells, regulation of interstitial fluid pressure, and angiogenesis. Recently, several drugs were developed that are potent inhibitors of the tyrosine kinase activity of PDGF receptors. Thus, it is important to understand the physiology of PDGF and its receptors and the role of PDGF in different diseases. This review summarizes the physiologic activity of PDGF, the expression of PDGF during embryonal development, and the roles of PDGF expression in nonmalignant disease and in different tumors.
引用
收藏
页码:1241 / 1257
页数:17
相关论文
共 206 条
[1]  
ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297
[2]   DEVELOPMENTAL PATTERNS OF PDGF B-CHAIN, PDGF-RECEPTOR, AND ALPHA-ACTIN EXPRESSION IN HUMAN GLOMERULOGENESIS [J].
ALPERS, CE ;
SEIFERT, RA ;
HUDKINS, KL ;
JOHNSON, RJ ;
BOWENPOPE, DF .
KIDNEY INTERNATIONAL, 1992, 42 (02) :390-399
[3]  
[Anonymous], HANDB EXP PHARM 1
[4]   Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].
Apperley, JF ;
Gardembas, M ;
Melo, JV ;
Russell-Jones, R ;
Bain, BJ ;
Baxter, J ;
Chase, A ;
Chessells, JM ;
Colombat, M ;
Dearden, CE ;
Dimitrijevic, S ;
Mahon, FX ;
Marin, D ;
Nikolova, Z ;
Olavarria, E ;
Silberman, S ;
Schultheis, B ;
Cross, NCP ;
Goldman, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487
[5]   Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate [J].
Ault, P ;
Cortes, J ;
Koller, C ;
Kaled, ES ;
Kantarjian, H .
LEUKEMIA RESEARCH, 2002, 26 (09) :881-884
[6]   The role of radiation therapy in the management of dermatofibrosarcoma protuberans [J].
Ballo, MT ;
Zagars, GK ;
Pisters, P ;
Pollack, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04) :823-827
[7]   Chordoma: Natural history and results in 28 patients treated at a single institution [J].
Baratti, D ;
Gronchi, A ;
Pennacchioli, E ;
Lozza, L ;
Colecchia, M ;
Fiore, A ;
Santinami, M .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) :291-296
[8]   Vascular development: Cellular and molecular regulation [J].
Beck, L ;
DAmore, PA .
FASEB JOURNAL, 1997, 11 (05) :365-373
[9]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591
[10]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295